Emori Y, Sasaki H, Hayashi Y, Nomoto K
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Saitama, Japan.
Biotherapy. 1996;9(4):249-56. doi: 10.1007/BF02620738.
In the present study, anti-metastatic effect of Z-100 on the spontaneous pulmonary metastases of Lewis lung carcinoma (3LL) was examined in an attempt to regulate suppressor T cells. When Z-100 (10 mg/kg) was daily injected i.p. after 3LL inoculation, survival rate of these mice was increased significantly (p < 0.05). In addition, the number of pulmonary metastatic colonies of 3LL in Z-100-treated mice were significantly decreased by 38% at 21 days, as compared with that of control mice (p < 0.05). Along with the decrease of pulmonary metastases, suppressor cell activity was also gradually reduced in these mice, as compared with that of control mice. When splenic suppressor cells (5 x 10(7) cells) from 3LL-bearing mice were adoptively transferred into normal mice (recipients) just before inoculation of 3LL, the development of pulmonary metastases in recipients was significantly accelerated. However, splenocytes from 3LL-bearing mice treated with Z-100 did not affect the development of pulmonary metastasis. The potential to accelerate the metastasis of splenic mononuclear cells from 3LL-bearing mice was decreased significantly by the treatment with anti-Thy 1.2 monoclonal antibody (mAb), anti-Lyt 2.2 mAb or anti-CD 11b mAb followed by complement. IL-4 activity in the sera of 3LL-bearing mice was detected 15 days after tumor inoculation (13 pg/ml) and gradually increased (18 pg/ml) 20 days after tumor inoculation. However, when Z-100 (10 mg/kg) was daily injected i.p., IL-4 activity in sera was decreased significantly, and the IL-4 activity was not detected in these mice on day 20. These results suggest that Z-100 could inhibit the pulmonary metastases in 3LL-bearing mice through the inhibition of suppressor T cell activity and a possible candidate of its effector molecule, IL-4.
在本研究中,为了调节抑制性T细胞,检测了Z - 100对Lewis肺癌(3LL)自发性肺转移的抗转移作用。在接种3LL后,每天腹腔注射Z - 100(10毫克/千克),这些小鼠的存活率显著提高(p < 0.05)。此外,与对照小鼠相比,Z - 100处理的小鼠在21天时3LL的肺转移瘤集落数量显著减少了38%(p < 0.05)。随着肺转移的减少,与对照小鼠相比,这些小鼠的抑制性细胞活性也逐渐降低。当在接种3LL之前,将来自荷3LL小鼠的脾抑制性细胞(5×10⁷个细胞)过继转移到正常小鼠(受体)中时,受体中肺转移的发生显著加速。然而,用Z - 100处理的荷3LL小鼠的脾细胞不影响肺转移的发生。用抗Thy 1.2单克隆抗体(mAb)、抗Lyt 2.2 mAb或抗CD 11b mAb处理荷3LL小鼠的脾单核细胞,随后进行补体处理,可显著降低其加速转移的能力。在接种肿瘤15天后,检测到荷3LL小鼠血清中的IL - 4活性为13皮克/毫升,接种肿瘤20天后逐渐升高至18皮克/毫升。然而,当每天腹腔注射Z - 100(10毫克/千克)时,血清中的IL - 4活性显著降低,在第20天时这些小鼠中未检测到IL - 4活性。这些结果表明,Z - 100可通过抑制抑制性T细胞活性及其效应分子IL - 4,来抑制荷3LL小鼠的肺转移。